

## Overview

### Useful For

Evaluation of tumor tissue to identify patients at high risk for having hereditary nonpolyposis colorectal cancer (HNPCC), also known as Lynch syndrome

Evaluation of tumor tissue to identify patients at risk for having hereditary endometrial carcinoma

### Reflex Tests

Test ID	Reporting Name	Available Separately	Always Performed
IHTOI	IHC Initial, Tech Only	No	No
IHTOA	IHC Additional, Tech Only	No	No

### Method Name

Immunohistochemistry

### NY State Available

Yes

## Specimen

### Specimen Type

TECHONLY

### Advisory Information

This test includes only technical performance of the stain (no pathologist interpretation is performed). If diagnostic consultation by a pathologist is required order PATHC / Pathology Consultation.

### Shipping Instructions

Attach the green pathology address label and the pink Immunostain Technical Only label included in the kit to the outside of the transport container.

### Necessary Information

If sending normal and tumor blocks; indicate the block number to be stained in performing lab notes (electronic orders) or on the enclosed paperwork (manual orders).

### Specimen Required

**Specimen Type:** Tissue

**Supplies:** Immunostain Technical Only Envelope (T693)

**Preferred:** 2 Unstained positively charged glass slides (25- x 75- x 1-mm) per test ordered; sections 4-microns thick.

**Acceptable:** Formalin-fixed, paraffin-embedded (FFPE) tissue block

### Digital Image Access

1. Information on accessing digital images of immunohistochemical (IHC) stains and the manual requisition form can be accessed through this website: [www.mayocliniclabs.com/test-info/ihc/index.html](http://www.mayocliniclabs.com/test-info/ihc/index.html)
2. Clients ordering stains using a manual requisition form will not have access to digital images.
3. Clients wishing to access digital images must place the order for IHC stains electronically. Information regarding digital imaging can be accessed through this website: [www.mayocliniclabs.com/test-info/ihc/faq.html](http://www.mayocliniclabs.com/test-info/ihc/faq.html)

### Forms

If not ordering electronically, complete, print, and send a [Immunohistochemical \(IHC\)/In Situ Hybridization \(ISH\) Stains Request](#) (T763) with the specimen.

### Reject Due To

Tissue/Other	Wet/frozen tissue Cytology smears Nonformalin-fixed tissue Nonparaffin-embedded tissue Noncharged slides ProbeOn slides
--------------	--

### Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
TECHONLY	Ambient (preferred)		
	Refrigerated		

## Clinical and Interpretive

### Clinical Information

[Hereditary nonpolyposis colorectal cancer \(HNPCC\), also known as Lynch syndrome, is an autosomal dominant hereditary cancer syndrome associated with germline mutations in the mismatch repair genes: \*MLH1\*, \*MSH2\*, \*MSH6\*, and \*PMS2\*.](#)

Lynch syndrome is predominantly characterized by significantly increased risks for colorectal and endometrial cancer. The lifetime risk for colorectal cancer is highly variable and dependent on the gene involved. The risk for colorectal cancer associated *MLH1* and *MSH2* mutations (approximately 50%-80%) is generally higher than the risks associated with mutations in the other Lynch syndrome-related genes and the lifetime risk for endometrial cancer (approximately 25%-60%) is also highly variable. Other malignancies within the tumor spectrum include sebaceous neoplasms, gastric cancer, ovarian cancer, hepatobiliary and urinary tract carcinomas, and small bowel cancer. The lifetime risks for these cancers are less than 15%. Of the 4 mismatch repair genes, mutations within the *PMS2* gene confer the lowest risk for any of the tumors within the Lynch syndrome spectrum.

Several clinical variants of Lynch syndrome have been defined. These include Turcot syndrome, Muir-Torre syndrome, and homozygous mismatch repair mutations (also called constitutional mismatch repair deficiency syndrome). Turcot syndrome and Muir-Torre syndrome are associated with increased risks for cancers within the

---

tumor spectrum described but also include brain and central nervous system malignancies and sebaceous carcinomas, respectively. Homozygous or compound heterozygous mismatch repair mutations, characterized by the presence of biallelic deleterious mutations within a mismatch repair gene, are associated with a different clinical phenotype defined by hematologic and brain cancers, cafe au lait macules, and childhood colon or small bowel cancer.

There are several strategies for evaluating individuals whose personal or family history of cancer is suggestive of Lynch syndrome. Testing tumors from individuals at risk for Lynch syndrome for microsatellite instability (MSI) indicates the presence or absence of defective DNA mismatch repair phenotype within the tumor, but does not suggest in which gene the abnormality rests. Tumors from individuals affected by Lynch syndrome usually demonstrate an MSI-H phenotype (MSI >30% of microsatellites examined). The MSI-H phenotype can also be seen in individuals whose tumors have somatic *MLH1* promoter hypermethylation. Tumors from individuals that show the MSS/MSI-L phenotype (MSI at <30% of microsatellites examined), are not likely to have Lynch syndrome or somatic hypermethylation of *MLH1*. Immunohistochemistry (IHC) is a complementary testing strategy to MSI testing. In addition to identifying tumors with defective DNA mismatch repair, IHC analysis is helpful for identifying the gene responsible for the defective DNA mismatch repair within the tumor, because the majority of MSI-H tumors show a loss of expression of at least 1 of the 4 mismatch repair genes described above.

Testing is typically first performed on the tumor of an affected individual and in the context of other risk factors, such as young age at diagnosis or a strong family history of Lynch syndrome-related cancers. If defective DNA mismatch repair is identified within the tumor, mutation analysis of the associated gene can be performed to identify the causative germline mutation and allow for predictive testing of at-risk individuals.

Of note, MSI-H phenotypes and loss of protein expression by IHC have also been demonstrated in various sporadic cancers, including those of the colon and endometrium. Absence of MLH1 and PMS2 protein expression within a tumor, for instance, is most often associated with a somatic alteration in individuals with an older age of onset of cancer than typical Lynch syndrome families. Therefore, an MSI-H phenotype or loss of protein expression by IHC within a tumor does not distinguish between somatic and germline mutations. Genetic testing of the gene indicated by IHC analysis can help to distinguish between these 2 possibilities. In addition, when absence of MLH1/PMS2 is observed, BRMLH / *MLH1* Hypermethylation and *BRAF* Mutation Analyses, Tumor or ML1HM / *MLH1* Hypermethylation Analysis, Tumor may also help to distinguish between a sporadic and germline etiology.

It should be noted that this Lynch syndrome screen is not a genetic test, but rather stratifies the risk of having an inherited cancer predisposition syndrome, and identifies patients who might benefit from subsequent genetic testing.

### **Interpretation**

This test includes only technical performance of the stain (no pathologist interpretation is performed). Mayo Clinic cannot provide an interpretation of tech only stains outside the context of a pathology consultation. If an interpretation is needed, refer to PATHC / Pathology Consultation for a full diagnostic evaluation or second opinion of the case. All material associated with the case is required. Additional specific stains may be requested as part of the pathology consultation, and will be performed as necessary at the discretion of the Mayo pathologist.

Â

The positive and negative controls are verified as showing appropriate immunoreactivity and documentation is retained at Mayo Clinic Rochester. If a control tissue is not included on the slide, a scanned image of the relevant quality control tissue is available upon request; contact 855-516-8404.

Â

Interpretation of this test should be performed in the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

---

**Cautions**

Age of a cut paraffin section can affect immunoreactivity. Stability thresholds vary widely among published literature and are antigen-dependent. Best practice is for paraffin sections to be cut fresh.

**Clinical Reference**

1. Burgart LJ: Testing for defective DNA mismatch repair in colorectal carcinoma: a practical guide. Arch Pathol Lab Med 2005;129:1385-1389
2. Klarskov L, Ladelund S, Holck S, et al: Interobserver variability in the evaluation of mismatch repair protein immunostaining. Hum Pathol 2010;41:1387-1396
3. Lanza G, Gafa R, Maestri I, et al: Immunohistochemical pattern of MLH1/MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability. Mod Pathol 2002;15(7):741-749
4. Modica I, Soslow RA, Black D, et al: Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma. Am J Surg Pathol 2007;31(5):744-751
5. Mojtahed A, Schrijver I, Ford JM, et al: A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas. Mod Pathol 2011;24:1004-1014
6. Rigau V, Sebbagh N, Olschwang S, et al: Microsatellite instability in colorectal carcinoma. The comparison of immunohistochemistry and molecular biology suggests a role for hMLH6 (correction of hMLH6) immunostaining. Arch Pathol Lab Med 2003;127:694-700
7. Shia J: Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn 2008;10(4):293-300

**Performance****Method Description**

Immunohistochemistry on sections of paraffin-embedded tissue.(Unpublished Mayo method)

**PDF Report**

No

**Day(s) and Time(s) Test Performed**

Monday through Friday

**Analytic Time**

1 day

**Maximum Laboratory Time**

3 days

**Specimen Retention Time**

Until staining is complete.

---

**Performing Laboratory Location**

Rochester

**Fees and Codes****Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact [Customer Service](#).

**Test Classification**

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

**CPT Code Information**

88342-TC, primary

88341-TC, if additional IHC

**LOINC® Information**

Test ID	Test Order Name	Order LOINC Value
MSH2	MSH2 IHC, Tech Only	Order only;no result

Result ID	Test Result Name	Result LOINC Value
70824	MSH2 IHC, Tech Only	Bill only; no result